NasdaqGM:ETONPharmaceuticals
How Q2 Profit Surge And Higher Guidance At Eton Pharmaceuticals (ETON) Has Changed Its Investment Story
In August 2026, Eton Pharmaceuticals reported second-quarter 2026 results showing revenue of US$37.59 million and net income of US$11.58 million, reversing a loss in the prior-year period and turning earnings per share from a loss to US$0.35 on a diluted basis.
Alongside this earnings improvement, the company raised its 2026 annual revenue guidance to at least US$145 million, suggesting management sees the recent performance as part of a broader shift in its operating profile.
With this...